Selective KIT Inhibitor Compounds for Mast Cell Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for KIT-mediated diseases, such as mastocytosis and severe asthma, are limited in specificity and can affect healthy cells, leading to potential side effects and incomplete eradication of mast cells.
Innovation Solution
Development of specific KIT inhibitors, represented by compounds of Formula (I) and their pharmaceutical compositions, to target and inhibit KIT activity in mast cells, thereby preventing or treating conditions like autoimmune diseases, allergic diseases, inflammatory diseases, fibrosis, and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum kinase inhibitors are used to treat KIT-mediated diseases, then KIT activity is inhibited, but healthy cells expressing KIT are also affected leading to side effects
Solution Approach 1:
The patent applies local quality by designing kinase inhibitors with specific molecular structures that selectively bind to KIT receptors in mast cells while sparing KIT receptors in other cell types. The compounds of Formula (I) are engineered with particular structural features that confer selectivity for mast cell KIT, thereby achieving targeted inhibition that eliminates therapeutic effects on healthy cells expressing KIT.
2Reliability
If current KIT inhibitors are used to eradicate mast cells, then KIT activity is reduced, but complete eradication is not achieved
Solution Approach 1:
The patent applies parameter changes by optimizing key molecular parameters of the kinase inhibitors, including binding affinity, selectivity, and potency. The compounds of Formula (I) are designed with specific structural parameters that enhance their ability to completely eradicate mast cells by achieving sufficient inhibition of KIT activity, overcoming the incomplete eradication limitation of current inhibitors.
3Measurement precision
If specific KIT inhibitors are developed to target mast cells, then treatment precision is improved, but treatment complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex task of achieving mast cell-selective KIT inhibition into manageable structural components. The compounds of Formula (I) are designed with specific modular structural elements that can be systematically optimized, allowing for precise targeting of mast cell KIT while maintaining reasonable structural complexity through organized molecular architecture.
Data Source
AI summary
Compounds and compositions that are useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or conditions, such as cancers, autoimmune diseases, allergic diseases, inflammatory diseases, fibrosis, metabolic disorders, and neurodegenerative diseases.